Meeting Banner
Abstract #2233

Detection of Treatment Effects with 1H MRS in Transgenic Mouse Model of Alzheimers Disease

Malgorzata Marjanska1, Stephen D. Weigand2, Geoffry L. Curran2, Thomas M. Wengenack2, Joseph F. Poduslo2, Michael Garwood1, Clifford R. Jack, Jr.2

1Radiology, University of Minnesota, Minneapolis, MN, United States; 2Mayo Clinic College of Medicine, Rochester, MN, United States

MRS was assessed as a non-invasive outcome measure capable of detecting metabolic alterations following passive immunization in a transgenic mouse model of Alzheimers disease (AD). Treatment of transgenic AD mice with either of two anti-A antibody regimes that have previously been demonstrated to reduce amyloid plaque load slowed the rate at which mIns normally increases in transgenic AD mice (APP-PS1) in a multi-dose treatment paradigm. 1H MRS may provide an in vivo measure of anti-Aβ therapeutic efficacy in pre-clinical studies.